International Journal of Cardiology
Volume 127, Issue 1 , Pages 27-32 , 23 June 2008

Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: Results of the BREATHE-5 open-label extension study

  • Michael A. Gatzoulis

      Affiliations

    • Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College, London, UK
    • Corresponding Author InformationCorresponding author. Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College, Sydney Street, London, SW3 6NP, UK. Tel.: +44 207 351 8602; fax: +44 207 351 8367.
    • ,
  • Maurice Beghetti

      Affiliations

    • Hôpital des Enfants, Geneva, Switzerland
    • ,
  • Nazzareno Galiè

      Affiliations

    • Istituto di Cardiologia, Università di Bologna, Bologna, Italy
    • ,
  • John Granton

      Affiliations

    • Toronto General Hospital, Toronto, Canada
    • ,
  • Rolf M.F. Berger

      Affiliations

    • University Medical Center Groningen, University of Groningen, The Netherlands
    • ,
  • Andrea Lauer

      Affiliations

    • Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
    • ,
  • Eleonora Chiossi

      Affiliations

    • Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
    • ,
  • Michael Landzberg

      Affiliations

    • Children's Hospital, Boston, MA, USA
    • ,
  • on behalf of the BREATHE-5 Investigators

Received 26 February 2007 ,Accepted 26 April 2007.

References 

  1. Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy for Eisenmenger's syndrome: a multi-centre, double-blind randomised placebo-controlled study. Circulation. 2006;114:48–54
  2. Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant. 1996;15:100–105
  3. Diller GP, Dimopoulos K, Okonko D, et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation. 2005;112:828–835
  4. Diller GP, Dimopoulos K, Broberg CS, et al. Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study. Eur Heart J. 2006;27:1737–1742
  5. Vongpatanasin W, Brickner ME, Hillis LD, Lange RA. The Eisenmenger syndrome in adults. Ann Intern Med. 1998;128:745–755
  6. Berman EB, Barst RJ. Eisenmenger's syndrome: current management. Prog Cardiovasc Dis. 2002;45:129–138
  7. Oya H, Nagaya N, Uematsu M, et al. Poor prognosis and related factors in adults with Eisenmenger syndrome. Am Heart J. 2002;143:739–744
  8. Daliento L, Somerville J, Presbitero P, et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J. 1998;19:1845–1855
  9. Galiè N, Hinderliter AL, Torbicki A, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41:1380–1386
  10. Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J. 1985;132:919–923
  11. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14:377–381
  12. Granton JT, Rabinovitch M. Pulmonary arterial hypertension in congenital heart disease. Cardiol Clin. 2002;20:441–457[vii]
  13. Schulze-Neick I, Gilbert N, Ewert R, et al. Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy. Am Heart J. 2005;150:716
  14. Gatzoulis MA, Rogers P, Li W, et al. Safety and tolerability of bosentan in adults with Eisenmenger physiology. Int J Cardiol. 2005;98:147–151
  15. Christensen DD, McConnell ME, Book WM, Mahle WT. Initial experience with bosentan therapy in patients with the Eisenmenger syndrome. Am J Cardiol. 2004;94:261–263
  16. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358:1119–1123
  17. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896–903
  18. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation. 1999;99:1858–1865
  19. Fernandes SM, Newburger JW, Lang P, et al. Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology. Am J Cardiol. 2003;91:632–635
  20. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165:800–804
  21. Galiè N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2002;39:1496–1502
  22. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41:2119–2125

PII: S0167-5273(07)01043-1

doi: 10.1016/j.ijcard.2007.04.078

International Journal of Cardiology
Volume 127, Issue 1 , Pages 27-32 , 23 June 2008

Article Tools

* Image Usage & Resolution